David V. Goeddel, Ph.D. co-founded Tularik, Inc. in November 1991. He was Vice President of Research until 1996 and then Chief Executive Officer until 2004, when Tularik was acquired by Amgen. He then served as Amgen’s first Senior Scientific Vice President until 2006. Prior to his tenure at Tularik, Dr. Goeddel was the first scientist hired by Genentech, serving in various positions including Fellow, Staff Scientist, and Director of Molecular Biology, from 1978 to 1993. His pioneering work in the fields of gene cloning and expression of human proteins has been the basis for five significant marketed therapeutics developed by Genentech, including human insulin, human growth hormone, interferon-alpha, interferon-gamma, and tissue plasminogen activator. Dr. Goeddel has received numerous scientific awards, including the Scheele Medal, the Eli Lilly Award in Biological Chemistry, the Inventor of the Year Award, the Jacob Heskel Gabbay Award, the Howley Prize for Arthritis Research, and the Warren Alpert Foundation Prize. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.